Taiwan Bio Therapeutics and TRACT Therapeutics Announce Successful Transfer of TRACT’s Regulatory T Cell Platform Technology to Taiwan Bio’s Manufacturing Facility
TRACT Therapeutics and Taiwan Bio Therapeutics Announce Poster Presentation at American Transplant Congress 2024
Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership
TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. FDA
Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells
TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™
Results of Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in Kidney Transplant Recipients
TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial
American Transplant Congress June 12, 2016
TRACT Therapeutics, Inc. Completes Phase I Safety Trial
International Society for Cellular Therapy
TRACT Therapeutics, Inc. in White City News